scholarly journals Herbal Products Used in Menopause and for Gynecological Disorders

Molecules ◽  
2021 ◽  
Vol 26 (24) ◽  
pp. 7421
Author(s):  
Maša Kenda ◽  
Nina Kočevar Glavač ◽  
Milan Nagy ◽  
Marija Sollner Dolenc ◽  
Keyword(s):  
Premenstrual Syndrome ◽  
Clinical Studies ◽  
Glycine Soja ◽  
Pharmacological Therapy ◽  
Menopausal Symptoms ◽  
Black Cohosh ◽  
Serious Adverse Events ◽  
Herbal Products ◽  
Evening Primrose ◽  
Gynecological Disorders

Herbal products are often used as an alternative to pharmacological therapy. Menopausal symptoms and gynecological disorders (such as premenstrual syndrome and dysmenorrhea) are the indications where pharmacological therapy may have serious adverse events, hence many women prefer to use herbal products to help with these symptoms. Here, we reviewed plants and derived products, which are commonly used for the abovementioned indications, focusing on clinical data, safely profile and whether or not their use is justified. We noted that limited data are available on the use of some plants for alleviating the symptoms of menopause and gynecological disorders. While black cohosh (Cimicifuga racemose) and red clover (Trifolium pretense) were consistently shown to help reduce menopausal symptoms in clinical studies, currently available data do not fully support the use of fenugreek (Trigonella foenum-graecum), hops (Humulus lupulus), valerian (Valeriana officinalis), and soybean (Glycine max and Glycine soja) for this indication. For premenstrual syndrome and premenstrual dysphoric disorder, chaste tree (Vitex agnus-castus) shows effectiveness, but more clinical studies are needed to confirm such effect upon the use of evening primrose (Oenothera biennis).

scholarly journals Herb–Drug Interactions: Worlds Intersect with the Patient at the Center

Medicines ◽  
2021 ◽  
Vol 8 (8) ◽  
pp. 44
Author(s):  
Mary Beth Babos ◽  
Michelle Heinan ◽  
Linda Redmond ◽  
Fareeha Moiz ◽  
Joao Victor Souza-Peres ◽  
...  
Keyword(s):  
Drug Interaction ◽  
Case Report ◽  
Drug Interactions ◽  
Clinical Studies ◽  
Drug Information ◽  
Case Reports ◽  
Full Information ◽  
Information Need ◽  
Herbal Products ◽  
Reduce Risk

This review examines three bodies of literature related to herb–drug interactions: case reports, clinical studies, evaluations found in six drug interaction checking resources. The aim of the study is to examine the congruity of resources and to assess the degree to which case reports signal for further study. A qualitative review of case reports seeks to determine needs and perspectives of case report authors. Methods: Systematic search of Medline identified clinical studies and case reports of interacting herb–drug combinations. Interacting herb–drug pairs were searched in six drug interaction resources. Case reports were analyzed qualitatively for completeness and to identify underlying themes. Results: Ninety-nine case-report documents detailed 107 cases. Sixty-five clinical studies evaluated 93 mechanisms of interaction relevant to herbs reported in case studies, involving 30 different herbal products; 52.7% of these investigations offered evidence supporting reported reactions. Cohen’s kappa found no agreement between any interaction checker and case report corpus. Case reports often lacked full information. Need for further information, attitudes about herbs and herb use, and strategies to reduce risk from interaction were three primary themes in the case report corpus. Conclusions: Reliable herb–drug information is needed, including open and respectful discussion with patients.

scholarly journals Black cohosh (Actaea racemosa) for the mitigation of menopausal symptoms: recent developments in clinical safety and efficacy

2006 ◽  
Vol 2 (5) ◽  
pp. 773-783 ◽  
Author(s):  
Gail B Mahady ◽  
Brian Doyle ◽  
Tracie Locklear ◽  
Scott J Cotler ◽  
Grace Guzman-Hartman ◽  
...  
Keyword(s):  
Menopausal Symptoms ◽  
Black Cohosh ◽  
Clinical Safety ◽  
Safety And Efficacy ◽  
Actaea Racemosa ◽  
Recent Developments

scholarly journals Intra-articular hyaluronic acid in the treatment of knee osteoarthritis: a Canadian evidence-based perspective

2017 ◽  
Vol 9 (9) ◽  
pp. 231-246 ◽  
Author(s):  
Mohit Bhandari ◽  
Raveendhara R. Bannuru ◽  
Eric M. Babins ◽  
Johanne Martel-Pelletier ◽  
Moin Khan ◽  
...  
Keyword(s):  
Hyaluronic Acid ◽  
Symptom Relief ◽  
Cochrane Review ◽  
Pharmacological Therapy ◽  
Therapeutic Effects ◽  
Loss Of Function ◽  
Serious Adverse Events ◽  
Knee Oa ◽  
Therapeutic Benefits ◽  
Increased Risk

Osteoarthritis (OA) is a chronic condition characterized by a loss of joint cartilage and is a major cause of disability in Canada, with an estimated CN$195 billion annual cost. Knee OA leads to persistent pain and loss of function, and treatment goals primarily focus on symptom relief and retention of function. Intra-articular hyaluronic acid (IAHA) has therapeutic benefits, and numerous recently published meta-analyses (MAs) and commentaries have highlighted new evidence on the role of IAHA therapy for knee OA. A diverse, multidisciplinary group of specialists met independently in closed sessions to review findings from eight MAs with literature search end dates no earlier than 2012 to address controversies surrounding IAHA therapy for mild-to-moderate knee OA within the Canadian treatment context. Outcomes from a total of eight MAs were reviewed, and consistent and statistically significant improvements in pain, function and stiffness up to 26 weeks were found with IAHA therapy compared with IA placebo or controls, regardless of MA size or trial quality. These findings are in line with those of a Cochrane review, another recent systematic review and patient satisfaction survey. Overall, three MAs reported outcomes based on molecular weight (MW), with the two reporting effect sizes showing significantly improved pain outcomes for higher compared with lower MW HAs. Recent evidence suggests that HA therapy is well tolerated with no increased risk of serious adverse events compared with placebo and the full therapeutic effect of IAHA therapy appears to have considerable clinical importance, consisting of the combined IA placebo and HA therapeutic effects. IAHA therapy is a well-tolerated and effective option for patients with mild-to-moderate knee OA failing first-line pharmacological therapy.

scholarly journals Review & meta-analysis: isopropanolic black cohosh extract iCR for menopausal symptoms – an update on the evidence

Climacteric ◽  
2020 ◽  
pp. 1-11
Author(s):  
C. Castelo-Branco ◽  
M. Gambacciani ◽  
A. Cano ◽  
M. J. Minkin ◽  
D. Rachoń ◽  
...  
Keyword(s):  
Meta Analysis ◽  
Menopausal Symptoms ◽  
Black Cohosh

scholarly journals Black Cohosh: Insights into its Mechanism(s) of Action

2008 ◽  
Vol 3 ◽  
pp. 117863370800300 ◽  
Author(s):  
Rachel L. Ruhlen ◽  
Grace Y. Sun ◽  
Edward R. Sauter
Keyword(s):  
Breast Cancer ◽  
Disease Risk ◽  
Hormone Replacement ◽  
Cardiovascular Disease Risk ◽  
Menopausal Symptoms ◽  
Black Cohosh ◽  
Preclinical Studies ◽  
Nitric Oxide Production ◽  
Health Initiative ◽  
Receptor Modulator

The Women's Health Initiative found that combination estrogen and progesterone hormone replacement therapy increases breast cancer and cardiovascular disease risk, which compelled many women to seek herbal alternatives such as black cohosh extract (BCE) to relieve their menopausal symptoms. While several clinical trials document the efficacy of BCE in alleviating menopausal symptoms, preclinical studies to determine how BCE works have yielded conflicting results. Part of this is because there is not a universally accepted method to standardize the dose of black cohosh triterpenes, the presumed active ingredients in the extract. Although the mechanism by which BCE relieves symptoms is unknown, several hypotheses have been proposed: it acts 1) as a selective estrogen receptor modulator, 2) through serotonergic pathways, 3) as an antioxidant, or 4) on inflammatory pathways. We found that while the most prominent triterpene in BCE, 23-epi-26-deoxyactein, suppresses cytokine-induced nitric oxide production in brain microglial cells, the whole BCE extract actually enhanced this pathway. A variety of activities have been reported for black cohosh and its compounds, but the absorption and tissue distribution of these compounds is unknown.

scholarly journals THE CONCEPT AND MANAGEMENT OF WAJAUL MAFASIL IN UNANI MEDICINE

2021 ◽  
pp. 7-13
Author(s):  
ZEHRA ZAIDI
Keyword(s):  
Side Effects ◽  
Clinical Studies ◽  
Pharmacological Therapy ◽  
Phase Iii ◽  
Herbal Drugs ◽  
Effective Management ◽  
Unani Medicine ◽  
Herbal Medications ◽  
Classical Knowledge

More than 54 million Americans suffer from some form of arthritis and 23.7 million are limited in their usual activity, primarily due to pain. The study aims to highlight the concept of Arthralgia and the potential of its management in Unani Medicines. Osteoarthritis (OA) is a slowly progressive condition with a variable prognosis. In general, predicting the prognosis in patients with OA is difficult. However, pharmacological therapy can be associated with serious side effects and high costs. Therefore, alternative therapies have been under investigation. Herbal medications have shown the potential for safe and effective management of arthritis. The Unani Medicine is a rich source of classical knowledge on arthritis. OA has been mentioned as Wajaul Mafasil Balghami/Saudawi, and Unani Physicians has been treating this disease successfully with mostly single herbal drugs and their compound formulations for centuries. It has been revealed through animal, in vitro, and clinical studies that most of the single and compound Unani formulations are safe, without any side effects, and effective in OA, especially gout and rheumatoid arthritis. There is a need to conduct studies at Phase III level after analyzing 2nd Phase clinical studies of Unani medicine, so a promising safe, economic, and effective treatment can be provided to the ailing society for OA.

Sign in / Sign up

Export Citation Format

Share Document